ibrutinib [Ligand Id: 6912] activity data from GtoPdb and ChEMBL

Click here for a description of the charts and data table

Please tell us if you are using this feature and what you think!

ChEMBL ligand: CHEMBL1873475 (CRA-032765, PC-32765, PCI-32765-00, PCI 32765, PCI-32765, Ibrutinib, Imbruvica)
There should be some charts here, you may need to enable JavaScript!
  • EPH receptor A2/Ephrin type-A receptor 2 in Human [ChEMBL: CHEMBL2068] [GtoPdb: 1822] [UniProtKB: P29317]
There should be some charts here, you may need to enable JavaScript!
  • epidermal growth factor receptor/Epidermal growth factor receptor erbB1 in Human [ChEMBL: CHEMBL203] [GtoPdb: 1797] [UniProtKB: P00533]
There should be some charts here, you may need to enable JavaScript!
  • fibroblast growth factor receptor 2/Fibroblast growth factor receptor 2 in Human [ChEMBL: CHEMBL4142] [GtoPdb: 1809] [UniProtKB: P21802]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • colony stimulating factor 1 receptor/Macrophage colony stimulating factor receptor in Human [ChEMBL: CHEMBL1844] [GtoPdb: 1806] [UniProtKB: P07333]
There should be some charts here, you may need to enable JavaScript!
  • platelet derived growth factor receptor beta/Platelet-derived growth factor receptor beta in Human [ChEMBL: CHEMBL1913] [GtoPdb: 1804] [UniProtKB: P09619]
There should be some charts here, you may need to enable JavaScript!
  • erb-b2 receptor tyrosine kinase 2/Receptor protein-tyrosine kinase erbB-2 in Human [ChEMBL: CHEMBL1824] [GtoPdb: 2019] [UniProtKB: P04626]
There should be some charts here, you may need to enable JavaScript!
  • erb-b2 receptor tyrosine kinase 4/Receptor protein-tyrosine kinase erbB-4 in Human [ChEMBL: CHEMBL3009] [GtoPdb: 1799] [UniProtKB: Q15303]
There should be some charts here, you may need to enable JavaScript!
There should be some charts here, you may need to enable JavaScript!
  • ABL proto-oncogene 1, non-receptor tyrosine kinase/Tyrosine-protein kinase ABL in Human [ChEMBL: CHEMBL1862] [GtoPdb: 1923] [UniProtKB: P00519]
There should be some charts here, you may need to enable JavaScript!
  • BLK proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase BLK in Human [ChEMBL: CHEMBL2250] [GtoPdb: 1940] [UniProtKB: P51451]
There should be some charts here, you may need to enable JavaScript!
  • BMX non-receptor tyrosine kinase/Tyrosine-protein kinase BMX in Human [ChEMBL: CHEMBL3834] [GtoPdb: 1942] [UniProtKB: P51813]
There should be some charts here, you may need to enable JavaScript!
  • protein tyrosine kinase 6/Tyrosine-protein kinase BRK in Human [ChEMBL: CHEMBL4601] [GtoPdb: 2182] [UniProtKB: Q13882]
There should be some charts here, you may need to enable JavaScript!
  • Bruton tyrosine kinase/Tyrosine-protein kinase BTK in Human [ChEMBL: CHEMBL5251] [GtoPdb: 1948] [UniProtKB: Q06187]
There should be some charts here, you may need to enable JavaScript!
  • C-terminal Src kinase/Tyrosine-protein kinase CSK in Human [ChEMBL: CHEMBL2634] [GtoPdb: 1994] [UniProtKB: P41240]
There should be some charts here, you may need to enable JavaScript!
  • FER tyrosine kinase/Tyrosine-protein kinase FER in Human [ChEMBL: CHEMBL3982] [GtoPdb: 2022] [UniProtKB: P16591]
There should be some charts here, you may need to enable JavaScript!
  • FGR proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase FGR in Human [ChEMBL: CHEMBL4454] [GtoPdb: 2024] [UniProtKB: P09769]
There should be some charts here, you may need to enable JavaScript!
  • FYN proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase FYN in Human [ChEMBL: CHEMBL1841] [GtoPdb: 2026] [UniProtKB: P06241]
There should be some charts here, you may need to enable JavaScript!
  • HCK proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase HCK in Human [ChEMBL: CHEMBL3234] [GtoPdb: 2032] [UniProtKB: P08631]
There should be some charts here, you may need to enable JavaScript!
  • IL2 inducible T cell kinase/Tyrosine-protein kinase ITK/TSK in Human [ChEMBL: CHEMBL2959] [GtoPdb: 2046] [UniProtKB: Q08881]
There should be some charts here, you may need to enable JavaScript!
  • Janus kinase 3/Tyrosine-protein kinase JAK3 in Human [ChEMBL: CHEMBL2148] [GtoPdb: 2049] [UniProtKB: P52333]
There should be some charts here, you may need to enable JavaScript!
  • LCK proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase LCK in Human [ChEMBL: CHEMBL258] [GtoPdb: 2053] [UniProtKB: P06239]
There should be some charts here, you may need to enable JavaScript!
  • LYN proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase Lyn in Human [ChEMBL: CHEMBL3905] [GtoPdb: 2060] [UniProtKB: P07948]
There should be some charts here, you may need to enable JavaScript!
  • fms related receptor tyrosine kinase 3/Tyrosine-protein kinase receptor FLT3 in Human [ChEMBL: CHEMBL1974] [GtoPdb: 1807] [UniProtKB: P36888]
There should be some charts here, you may need to enable JavaScript!
  • ret proto-oncogene/Tyrosine-protein kinase receptor RET in Human [ChEMBL: CHEMBL2041] [GtoPdb: 2185] [UniProtKB: P07949]
There should be some charts here, you may need to enable JavaScript!
  • SRC proto-oncogene, non-receptor tyrosine kinase/Tyrosine-protein kinase SRC in Human [ChEMBL: CHEMBL267] [GtoPdb: 2206] [UniProtKB: P12931]
There should be some charts here, you may need to enable JavaScript!
  • spleen associated tyrosine kinase/Tyrosine-protein kinase SYK in Human [ChEMBL: CHEMBL2599] [GtoPdb: 2230] [UniProtKB: P43405]
There should be some charts here, you may need to enable JavaScript!
  • tec protein tyrosine kinase/Tyrosine-protein kinase TEC in Human [ChEMBL: CHEMBL4246] [GtoPdb: 2238] [UniProtKB: P42680]
There should be some charts here, you may need to enable JavaScript!
  • TXK tyrosine kinase/Tyrosine-protein kinase TXK in Human [ChEMBL: CHEMBL4367] [GtoPdb: 2268] [UniProtKB: P42681]
There should be some charts here, you may need to enable JavaScript!
  • YES proto-oncogene 1, Src family tyrosine kinase/Tyrosine-protein kinase YES in Human [ChEMBL: CHEMBL2073] [GtoPdb: 2284] [UniProtKB: P07947]
There should be some charts here, you may need to enable JavaScript!
DB Assay description Assay Type Standard value Standard parameter Original value Original units Original parameter Reference
cyclin dependent kinase 2/Cyclin-dependent kinase 2/cyclin E1 in Human (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL1907605] [GtoPdb: 1973] [UniProtKB: P24864, P24941]
ChEMBL Inhibition of His-tagged CDK2/Cyclin-E1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured in presence of [gamma-33P]ATP B 4.6 pIC50 >25000 nM IC50 J Med Chem (2019) 62: 4606-4623 [PMID:30943029]
EPH receptor A2/Ephrin type-A receptor 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2068] [GtoPdb: 1822] [UniProtKB: P29317]
ChEMBL Inhibition of recombinant human EPHA2 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 6 pIC50 >1000 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
epidermal growth factor receptor/Epidermal growth factor receptor erbB1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL203] [GtoPdb: 1797] [UniProtKB: P00533]
ChEMBL Inhibition of recombinant human GST-tagged EGFR L858R/T790M double mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 20 mins by HTRF assay B 6.41 pIC50 390 nM IC50 J Med Chem (2017) 60: 7725-7744 [PMID:28853575]
ChEMBL Inhibition of recombinant human N-terminal GST-tagged wild-type EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay B 6.91 pIC50 123 nM IC50 Eur J Med Chem (2017) 131: 107-125 [PMID:28315597]
ChEMBL Inhibition of human recombinant GST-tagged EGFR L858R mutant expressed in baculovirus expression system preincubated for 30 mins followed by ATP and TK-substrate addition measured after 15 mins by HTRF assay B 6.92 pIC50 120 nM IC50 J Med Chem (2017) 60: 7725-7744 [PMID:28853575]
ChEMBL Inhibition of EGFR L858R/T790M double mutant (unknown origin) by HTRF assay B 7.4 pIC50 40 nM IC50 J Med Chem (2019) 62: 2843-2848 [PMID:30768270]
ChEMBL Inhibition of human recombinant EGFR using Ulight-CAGAGAIETDKEYYTVKD measured after 15 mins in the presence of ATP by LANCE method B 7.92 pIC50 12 nM IC50 Eur J Med Chem (2019) 169: 121-143 [PMID:30875504]
ChEMBL Inhibition of EGFR (unknown origin) B 7.92 pIC50 12 nM IC50 Bioorg Med Chem (2019) 27: 3390-3395 [PMID:31221612]
ChEMBL Inhibition of ErbB1 relative to control B 8.25 pIC50 5.6 nM IC50 Bioorg. Med. Chem. Lett. (2011) 21: 6258-6263 [PMID:21958547]
ChEMBL Inhibition of EGFR (unknown origin) B 8.25 pIC50 5.6 nM IC50 Bioorg Med Chem Lett (2017) 27: 4171-4175 [PMID:28734581]
GtoPdb - - 8.28 pIC50 5.3 nM IC50 N Engl J Med (2016) 374: 323-32 [PMID:26641137]
ChEMBL Inhibition of wild type EGFR (unknown origin) by HTRF assay B 9 pIC50 <1 nM IC50 J Med Chem (2019) 62: 2843-2848 [PMID:30768270]
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.3 pIC50 0.5 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.3 pIC50 0.5 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.3 pIC50 0.5 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.3 pIC50 0.5 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
fibroblast growth factor receptor 2/Fibroblast growth factor receptor 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4142] [GtoPdb: 1809] [UniProtKB: P21802]
ChEMBL Inhibition Assay: When setting conditions for the measurement of the inhibitory effect of the compounds on FGFR2 kinase activity, FL-Peptide 22 (Caliper Life Sciences, Inc.) was used as a substrate. The purified recombinant human FGFR2 protein used in the test was purchased from Carna Biosciences, Inc. In the measurement of the inhibitory effect of the compounds, first, a test compound was gradually diluted with dimethylsulfoxide (DMSO) to a concentration that was 20 times higher than the final concentration. Next, the purified human FGFR2 protein, FL-Peptide 22 (final concentration: 1.5 .mu.M), magnesium chloride (final concentration: 5 mM), ATP (final concentration: 75 .mu.M), and the test compound DMSO solution (final concentration of DMSO: 5%) were added to a reaction buffer (15 mM Tris-HCl pH 7.5, 0.01% Tween-20, 2 mM DTT), and the mixture was incubated at 25.degree. C. for 120 minutes to perform a kinase reaction. EDTA (final concentration: 30 mM) diluted with a separation buffer. B 6.55 pIC50 280 nM IC50 US-9108973-B2. 3,5-disubstituted alkynylbenzene compound and salt thereof (2015)
Kv11.1/HERG in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL240] [GtoPdb: 572] [UniProtKB: Q12809]
ChEMBL Binding affinity to human ERG B 5.96 pKi 1100 nM Ki Bioorg Med Chem Lett (2018) 28: 2939-2944 [PMID:30122225]
ChEMBL Inhibition of human ERG B 5.96 pIC50 1100 nM IC50 Bioorg Med Chem Lett (2018) 28: 3307-3311 [PMID:30243592]
colony stimulating factor 1 receptor/Macrophage colony stimulating factor receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1844] [GtoPdb: 1806] [UniProtKB: P07333]
ChEMBL Inhibition of recombinant human CSF1R using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 6 pIC50 >1000 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
platelet derived growth factor receptor beta/Platelet-derived growth factor receptor beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1913] [GtoPdb: 1804] [UniProtKB: P09619]
ChEMBL Inhibition of recombinant human PDGFR-beta using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 6 pIC50 >1000 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
erb-b2 receptor tyrosine kinase 2/Receptor protein-tyrosine kinase erbB-2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1824] [GtoPdb: 2019] [UniProtKB: P04626]
ChEMBL Binding affinity to DNA-tagged recombinant ERBB2 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis B 8.92 pKd 1.2 nM Kd J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL Inhibition of human recombinant HER2 using biotinyl-beta amyloid beta amyloid beta AAEEEEYFELVAKKK measured after 10 mins in the presence of ATP by HTRF assay B 7.66 pIC50 22 nM IC50 Eur J Med Chem (2019) 169: 121-143 [PMID:30875504]
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 8.03 pIC50 9.4 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL Inhibition of Her2 (unknown origin) B 8.03 pIC50 9.4 nM IC50 Bioorg Med Chem Lett (2017) 27: 4171-4175 [PMID:28734581]
ChEMBL Inhibition of human ErbB2 using using poly (4:1 Glu, Tyr) as substrate measured after 1 hr in presence of [gamma-33P]ATP B 8.03 pIC50 9.4 nM IC50 MedChemComm (2018) 9: 697-704
GtoPdb - - 8.19 pIC50 6.4 nM IC50 N Engl J Med (2016) 374: 323-32 [PMID:26641137]
ChEMBL Inhibition of recombinant human ErbB2 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 8.82 pIC50 1.5 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
erb-b2 receptor tyrosine kinase 4/Receptor protein-tyrosine kinase erbB-4 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3009] [GtoPdb: 1799] [UniProtKB: Q15303]
ChEMBL Binding affinity to DNA-tagged recombinant ERBB4 (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis B 8.62 pKd 2.4 nM Kd J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 8.03 pIC50 9.4 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
GtoPdb - - 8.47 pIC50 3.4 nM IC50 N Engl J Med (2016) 374: 323-32 [PMID:26641137]
ChEMBL Inhibition of recombinant human ErbB4 using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 8.74 pIC50 1.8 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
ChEMBL Inhibition of HER4 (unknown origin) B 9.22 pIC50 0.6 nM IC50 Eur J Med Chem (2019) 169: 121-143 [PMID:30875504]
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 10 pIC50 0.1 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 10 pIC50 0.1 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
Redox-regulatory protein FAM213A in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3879824] [UniProtKB: Q9BRX8]
ChEMBL Inhibition of PF-06658607 binding to recombinant C-terminal FLAG-tagged FAM213A (unknown origin) expressed in HEK293T cells after 1 hr by gel-based ABPP assay B 6.05 pIC50 900 nM IC50 Nat Rev Drug Discov (2017) 16: 424-440 [PMID:28280261]
ABL proto-oncogene 1, non-receptor tyrosine kinase/Tyrosine-protein kinase ABL in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1862] [GtoPdb: 1923] [UniProtKB: P00519]
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 7.06 pIC50 86.1 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 7.06 pIC50 86.1 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
BLK proto-oncogene, Src family tyrosine kinase/Tyrosine-protein kinase BLK in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2250] [GtoPdb: 1940] [UniProtKB: P51451]
GtoPdb - - 9.3 pIC50 0.5 nM IC50 J Med Chem (2012) 55: 4539-50 [PMID:22394077]
ChEMBL Inhibition of BLK B 9.3 pIC50 0.5 nM IC50 J. Med. Chem. (2012) 55: 4539-4550 [PMID:22394077]
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.3 pIC50 0.5 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.3 pIC50 0.5 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
ChEMBL Inhibition of recombinant human BLK using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 9.3 pIC50 0.5 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
GtoPdb - - 10 pIC50 0.1 nM IC50 N Engl J Med (2016) 374: 323-32 [PMID:26641137]
BMX non-receptor tyrosine kinase/Tyrosine-protein kinase BMX in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3834] [GtoPdb: 1942] [UniProtKB: P51813]
ChEMBL Binding affinity to DNA-tagged recombinant BMX (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis B 8.8 pKd 1.6 nM Kd J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL Inhibition of full length recombinant human N-terminal GST-tagged BMX expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay B 8.1 pIC50 8 nM IC50 Eur J Med Chem (2017) 131: 107-125 [PMID:28315597]
ChEMBL Inhibition of recombinant human BMX using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 8.24 pIC50 5.8 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
ChEMBL Inhibition of BMX B 9.1 pIC50 0.8 nM IC50 J. Med. Chem. (2012) 55: 4539-4550 [PMID:22394077]
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.1 pIC50 0.8 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 9.1 pIC50 0.8 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
ChEMBL Inhibition of BMX (unknown origin) B 9.1 pIC50 0.8 nM IC50 Bioorg Med Chem Lett (2017) 27: 4171-4175 [PMID:28734581]
GtoPdb - - 9.1 pIC50 0.8 nM IC50 N Engl J Med (2016) 374: 323-32 [PMID:26641137]
GtoPdb - - 9.1 pIC50 0.8 nM IC50 J Med Chem (2012) 55: 4539-50 [PMID:22394077]
protein tyrosine kinase 6/Tyrosine-protein kinase BRK in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4601] [GtoPdb: 2182] [UniProtKB: Q13882]
ChEMBL HotSpot kinase assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kinase assay. Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 8.48 pIC50 3.3 nM IC50 US-9181263-B2. Inhibitors of bruton's tyrosine kinase (2015)
ChEMBL In Vitro HotSpot Kinase Assay: IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction conditions were 1 uM ATP, one hour incubation with inhibitor, and kinase activity detected using 33-ATP phosphorylation of an appropriately selected peptide substrate. B 8.48 pIC50 3.3 nM IC50 US-9278100-B2. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors (2016)
Bruton tyrosine kinase/Tyrosine-protein kinase BTK in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5251] [GtoPdb: 1948] [UniProtKB: Q06187]
ChEMBL Binding affinity to DNA-tagged recombinant BTK (unknown origin) measured after 1 hr by biotinylated-ligand affinity bead-based qPCR analysis B 8.72 pKd 1.9 nM Kd J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL Reversible inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 2 to 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay B 8.32 pKi 4.8 nM Ki Eur J Med Chem (2017) 131: 107-125 [PMID:28315597]
ChEMBL Inhibition of BTK in human basophils assessed as reduction in anti-IgE mouse IgG1 antibody Le2-stimulated CD63 expression on basophil preincubated for 30 mins in presence of IgE antibody B11 followed by anti-IgE mouse IgG1 antibody Le2 stimulation and measured after 15 mins by flow cytometry B 6.64 pIC50 230 nM IC50 J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL Inhibition of BTK in human whole blood derived-basophils assessed as suppression of IgE mediated-FcepsilonR ligation-stimulated CD63 expression B 6.77 pIC50 171 nM IC50 J Med Chem (2018) 61: 2227-2245 [PMID:29457982]
ChEMBL Inhibition of BTK in human B cells assessed as reduction in anti-IgM/IL4-stimulated CD69 expression on B cells preincubated for 60 mins followed by anti-IgM antibody/IL4 stimulation and measured after 16 hrs by flow cytometry B 7.18 pIC50 66 nM IC50 J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL Inhibition of human recombinant full length N-terminal His tagged BTK C481S mutant expressed in baculovirus infected Sf9 cells using poly (Glu,Tyr) 4:1 as substrate measured after 60 mins in presence of ATP by ADP-Glo kinase assay B 7.77 pIC50 17 nM IC50 Eur J Med Chem (2019) 178: 767-781 [PMID:31234030]
ChEMBL Inhibition of BTK in vitamin D3 differentiated human THP1 cells assessed as inhibition of FCgammaR-induced IL8 production measured after 24 hrs by HTRF assay B 7.8 pIC50 16 nM IC50 J Med Chem (2020) 63: 5102-5118 [PMID:32083858]
ChEMBL Inhibition of recombinant full-length N-terminal His-tagged human BTK C481S mutant expressed in baculovirus infected Sf9 insect cells using Poly(Glu, Tyr) 4:1 as substrate after 1 hr by ELISA B 7.84 pIC50 14.4 nM IC50 J Med Chem (2018) 61: 4608-4627 [PMID:29715023]
ChEMBL Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis B 7.85 pIC50 14 nM IC50 J. Med. Chem. (2014) 57: 5112-5128 [PMID:24915291]
ChEMBL Inhibition of BTK in whole blood (unknown origin) B 7.85 pIC50 14 nM IC50 Bioorg Med Chem Lett (2018) 28: 2939-2944 [PMID:30122225]
ChEMBL Inhibition of BTK in human WBC B 7.85 pIC50 14 nM IC50 Bioorg Med Chem Lett (2018) 28: 3307-3311 [PMID:30243592]
ChEMBL Inhibition of BTK in human whole blood B 7.85 pIC50 14 nM IC50 Bioorg Med Chem Lett (2018) 28: 3419-3424 [PMID:30290988]
ChEMBL Inhibition of full length recombinant human N-terminal His tagged BKT expressed in baculovirus infected Sf9 insect cells using poly (Glu,Tyr)4:1 as substrate pretreated for 60 mins followed by substrate addition after 1 hr by ADP-Glo luminescence assay B 7.92 pIC50 12 nM IC50 Eur J Med Chem (2017) 131: 107-125 [PMID:28315597]
ChEMBL Inhibition of BTK in human whole blood-derived CD19+ B cells assessed as suppression of anti-IgM stimulated-CD69 expression preincubated for 1 hr followed by IgM stimulation for 18 hrs by FACS analysis B 7.92 pIC50 12 nM IC50 J Med Chem (2018) 61: 2227-2245 [PMID:29457982]
ChEMBL Inhibition of Btk phosphorylation at Tyr551 in human Ramos cells after 1 hr by Western blot analysis B 8.12 pIC50 >7.5 nM IC50 J. Med. Chem. (2014) 57: 5112-5128 [PMID:24915291]
ChEMBL Inhibition of full length human N-terminal GST-tagged BTK (2 to 659 residues) expressed in baculovirus expression system using biotinylated substrate after 50 mins by HTRF assay B 8.26 pIC50 5.49 nM IC50 Bioorg Med Chem (2018) 26: 2165-2172 [PMID:29567295]
ChEMBL Inhibition of recombinant full-length human N-terminal GST-fused BTK (2 to 659 residues) expressed in baculovirus expression system using biotin-labelled peptide as substrate measured after 50 mins by TR-FRET assay B 8.26 pIC50 5.49 nM IC50 Bioorg Med Chem Lett (2019) 29: 225-229 [PMID:30522954]
ChEMBL Inhibition of BTK in human PBMC assessed as reduction in anti-IgM-induced CD69 expression incubated for 1 hr by flow cytometric analysis B 8.34 pIC50 4.6 nM IC50 Bioorg Med Chem Lett (2018) 28: 2939-2944 [PMID:30122225]